KLRS
Income statement / Annual
Last year (2023), Kalaris Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Kalaris Therapeutics Inc's net income was -$14.70 M.
See Kalaris Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
Period Ended |
12/31/2023 |
12/31/2022 |
Operating Revenue |
$0.00 |
$0.00 |
Cost of Revenue |
$0.00
|
$0.00
|
Gross Profit |
$0.00
|
$0.00
|
Gross Profit Ratio |
0
|
0
|
Research and Development Expenses |
$11.71 M
|
$11.76 M
|
General & Administrative Expenses |
$1.76 M
|
$2.24 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$1.76 M
|
$2.24 M
|
Other Expenses |
$0.00
|
$0.00
|
Operating Expenses |
$13.46 M
|
$14.01 M
|
Cost And Expenses |
$13.46 M
|
$14.01 M
|
Interest Income |
$0.00
|
$0.00
|
Interest Expense |
$687.00 K
|
$235.00 K
|
Depreciation & Amortization |
$0.00
|
$0.00
|
EBITDA |
-$14.01 M |
-$15.25 M |
EBITDA Ratio |
0
|
0
|
Operating Income Ratio |
0
|
0
|
Total Other Income/Expenses Net |
-$1.24 M
|
-$1.48 M
|
Income Before Tax |
-$14.70 M
|
-$15.49 M
|
Income Before Tax Ratio |
0
|
0
|
Income Tax Expense |
$0.00
|
$0.00
|
Net Income |
-$14.70 M
|
-$15.49 M
|
Net Income Ratio |
0
|
0
|
EPS |
0 |
0 |
EPS Diluted |
0 |
0 |
Weighted Average Shares Out |
$0.00
|
$0.00
|
Weighted Average Shares Out Diluted |
$0.00
|
$0.00
|
Link |
|
|